Kawai, Yuko
Nagayama, Aiko https://orcid.org/0000-0002-7453-8132
Miyao, Kazuhiro
Takeuchi, Makoto
Yokoe, Takamichi
Kameyama, Tomoe
Wang, Xinyue
Seki, Tomoko
Takahashi, Maiko
Hayashida, Tetsu
Kitagawa, Yuko
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K17592, Fujita Memorial Fund for Medical Research)
School of Medicine, Keio University (Academic Development Funds)
Article History
Received: 24 May 2024
Accepted: 26 September 2024
First Online: 1 October 2024
Declarations
:
: A. Nagayama reports ownership of Chugai Pharmaceutical stock; lecture fees from Daiichi Sankyo, Pfizer, and Chugai. T. Hayashida reports grants from Eli Lilly Japan K.K. and lecture fees from Eli Lilly Japan K.K. and Pfizer. Y. Kitagawa reports grants and personal fee from Asahi Kasei Pharma Corporation, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Tsumura & Co., Takeda Pharmaceutical Co., Ltd., grants from Nippon Covidien Inc., Yakult Honsha Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Teijin Pharma Ltd., Cardinal Health., and Kowa Company, Ltd.. Y. Kitagawa reports personal fee from AstraZeneca K.K., Ethicon Inc., Olympus Corporation, Cardinal Health K.K., Shionogi & Co., Ltd., Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew KK, ASKA Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co. Ltd., Toray Industries, Inc., Daiichi Sankyo Co, Ltd, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku Co., Ltd., Intuitive Surgical G.K., and SYSMEX CORPORATION. No disclosures were reported by the other authors.
: This article does not contain any studies with human participants performed by any of the authors. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.